EXPERIMENTAL DRUG DEVELOPMENT CENTR AGENCY FOR SCIENCE 10 BIOPOLIS ROA TECHNOLOGY AND RESEARCH 05 01

Address: 10 Biopolis Road, #05-01, Chromos, Singapore 138670

Company Profile:

The Experimental Drug Development Centre (EDDC) is a national platform under Singapore's Agency for Science, Technology and Research (A*STAR). It serves as a professional drug discovery and development unit that bridges the gap between early-stage academic research and clinical development. The organization focuses on translating innovative scientific discoveries into potential new medicines. It provides expertise in areas such as medicinal chemistry, biology, pharmacology, and drug metabolism, collaborating with both public and private sectors to advance therapeutic candidates toward clinical trials.

Business Type:

Research and Development Institution (Neither a manufacturing factory nor a traditional trading company).

Experimental Drug Development Centre (EDDC) is a national platform under the Agency for Science, Technology and Research (A*STAR) in Singapore. It does not function as a traditional commercial company that sells off-the-shelf products. Instead, it operates as a drug discovery and development organization that produces research outcomes, clinical candidates, and intellectual property.

Its primary outputs include:

1. Small Molecule Drug Candidates: Novel chemical entities developed for various therapeutic areas, particularly oncology and infectious diseases, aimed at progressing into clinical trials.

2. Biologic Drug Candidates: Development of therapeutic antibodies or other protein-based modalities targeting specific disease pathways.

3. Assay Development and Screening Platforms: Proprietary methodologies and high-throughput screening assays used to identify potential drug leads from chemical libraries.

4. Translational Research Data: Preclinical data packages, including pharmacological, pharmacokinetic, and toxicological profiles, which are used to support Investigational New Drug (IND) applications.

5. Intellectual Property (IP): Patents and licensing opportunities for novel drug targets, chemical scaffolds, and therapeutic technologies, which are typically out-licensed to pharmaceutical or biotechnology partners for further clinical development and commercialization.

6. Collaborative Research Services: Providing specialized drug discovery expertise, medicinal chemistry, and structural biology support to academic and industrial partners through research collaborations.